Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00337779 |
Recruitment Status :
Completed
First Posted : June 16, 2006
Results First Posted : May 14, 2010
Last Update Posted : October 10, 2011
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Relapsing Remitting Multiple Sclerosis | Drug: Glatiramer Acetate (GA) 40 mg Drug: glatiramer acetate 20 mg | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 1155 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Multinational, Multicenter, Randomized, Parallel-Group, Double-Blind Study to Compare the Efficacy, Tolerability and Safety of Glatiramer Acetate Injection 40 mg/ml to That of Glatiramer Acetate Injection 20 mg/ml Administered Once Daily by Subcutaneous Injection in Subjects With Relapsing Remitting (R-R) Multiple Sclerosis (MS) |
Study Start Date : | August 2006 |
Actual Primary Completion Date : | October 2008 |
Actual Study Completion Date : | October 2008 |

Arm | Intervention/treatment |
---|---|
Active Comparator: glatiramer acetate 40 mg |
Drug: Glatiramer Acetate (GA) 40 mg
Glatiramer Acetate Injection 40 mg/ml Daily subcutaneous injection for 12 months
Other Name: Copaxone® |
Active Comparator: glatiramer acetate 20 mg |
Drug: glatiramer acetate 20 mg
Glatiramer Acetate Injection 20 mg/ml Daily subcutaneous injection for 12 months
Other Name: Copaxone® |
- The Rate of Confirmed Relapses During the Double-blind Phase (12 Months). [ Time Frame: 12 months ]A confirmed relapse is defined as the appearance of one or more new neurological abnormalities or the reappearance of one or more previously observed neurological abnormalities. This change in clinical state must last at least 48 hours and be immediately preceded by an improving neurological state of at least thirty (30) days from onset of previous relapse.
- The Number of New T2 Lesions at Month 12 as Compared to the Baseline Scan. [ Time Frame: 12 months ]The analysis of this endpoint was based on the outcome of a contrast derived from a baseline-adjusted Negative Binomial Regression including the number of T1 Gd-enhancing lesions at baseline, the volume of T2 lesions at baseline and (pooled) center as covariates.
- The Cumulative Number of T1-Gd Enhancing Lesions at Months 3, 6, 9 and 12 (in the Frequent MRI Cohort-described Below). [ Time Frame: 12 months ]The Frequent MRI Cohort was a subset of subjects consisting of 234 subjects, for whom MRI scans were performed at months 0 (baseline), 1, 2, 3, 6, 9 and 12. Analysis of the endpoint was based on the outcome of a contrast derived from a baseline-adjusted Negative Binomial Regression with an "offset" variable employing the log of the porportion of the number of available post-baseline scans to adjust for missing MRI scans (if any) and including the number of T1 Gd-enhancing lesions at baseline and (pooled) center as covariates.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of confirmed and documented MS defined by the Revised McDonald criteria.
- Subjects must be of the relapsing-remitting (R-R) type.
- Subject has experienced prior to screening at least one documented relapse in 12 months or at least 2 documented relapses in the 24 months or one documented relapse between 12 - 24 months with at least 1 documented T1-Gd enhancing lesion in the MRI performed 12 months prior screening.
- Disease duration for at least 6 months.
- Ambulatory with converted Kurtzke EDSS score of 0 - 5.
- Relapse free and stable neurological condition at least for 30 days prior screening.
- Age - 18-55 (inclusive)
Exclusion Criteria:
- Previous use of Copaxone (glatiramer acetate)
- Treatment with corticosteroids within 30 days prior screening or between screening and baseline.
- Chronic corticosteroids treatment - more than 30 consecutive days.
- Subject with any clinically significant or unstable medical condition.
- Subjects participating in any other clinical trial (within 12 weeks prior to screening and thereafter).
- Known history of sensitivity to Gadolinium and inability to successfully undergo MRI scanning.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00337779
Study Chair: | Chen Duksin, MD | Teva Pharmaceutical Industries, Ltd. | |
Principal Investigator: | Giancarlo Comi, Prof | Istituto Scientifico Fondazione Centro S. Raffaele |
Responsible Party: | Teva Branded Pharmaceutical Products R&D, Inc. |
ClinicalTrials.gov Identifier: | NCT00337779 |
Other Study ID Numbers: |
GA/9016 (FORTE) |
First Posted: | June 16, 2006 Key Record Dates |
Results First Posted: | May 14, 2010 |
Last Update Posted: | October 10, 2011 |
Last Verified: | October 2011 |
Multiple Sclerosis Multiple Sclerosis, Relapsing-Remitting Sclerosis Pathologic Processes Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System Nervous System Diseases Demyelinating Diseases Autoimmune Diseases |
Immune System Diseases Glatiramer Acetate (T,G)-A-L Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Immunosuppressive Agents Antirheumatic Agents |